STOCKS TELEGRAPH

Tag: CAPR

  • Here’s the Reason Why Capricor Therapeutics, Inc. (CAPR) Stock is Roaring in the Premarket

    Capricor Therapeutics, Inc. (CAPR) is a biopharmaceutical company engaged in the development of therapeutics for treating an array of diseases. The company’s pipeline product candidate includes CAP-1002 used for treating Duchenne muscular dystrophy and the cytokine storm in COVID-19 patients. The Company is also developing exosomes capable of delivering nucleic acids to treat different diseases.

    The price of CAPR stock during the regular trading on January 24, 2022 was $2.83 with a decline of 2.08%. At last check in the premarket on January 25, 2022, the stock was significantly up by 7.42%.

    CAPR: Events and Happenings

    On January 25, 2022, CAPR reported about its entry into strategic collaboration with Japanese origin Nippon Shinyaku Company. The basic aim of the partnership is the commercialization and distribution of CAP-1002 in the US. On December 13, 2021, CAPR reported its vaccine and developmental portfolio updates mainly focusing on COVID-19. Company’s pre-clinical exosome mRNA vaccine has the capability for a strong T-cell response in a viral infection. In addition, the company will also report topline results from its INSPIRE Phase 2 studies in Q1 2022.

    On November 12, 2021, CAPR reported that the company’s Executives presented at the Virtual TriLink Biotechnologies Annual mRNA Day Conference held on November 16, 2021.

    CAPR: Key Financials

    On November 09, 2021, CAPR announced its financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows.

    Net Loss per Share

    Basic and diluted net loss per share in Q3 2021 was $3.9 million, or $0.17 compared to $3.9 million, or $0.20 for the same period in 2020.

    Assets

    Total assets in Q3 2021 were recorded to be $43.1 million.

    On September 24, 2021, CAPR reported optimistic final results for its HOPE-2 clinical studies utilizing CAP-1002. On September 22, 2021, CAPR reported that the company’s Executives presented at the conferences namely Virtual Cantor Fitzgerald Global healthcare Conference held on September 30 and Cell & Gene Meeting on the Mesa held on October 13, 2021.

    Conclusion

    CAPR stock is 40% down compared to the last six months period due to the challenges faced by the economy because of the worsening pandemic situation. The current premarket increase in stock price is the consequence of the company’s announcement of its entry into a strategic partnership. The analysts are confident that the current market scenario is favorable for the company’s stock to bloom.

  • 15 Trending Stocks in Biotechnology Industry

    15 Trending Stocks in Biotechnology Industry

    The biggest movers of the 2020 are biotech stocks. Now, the COVID-19 pandemic has put brighter spotlight on the future of healthcare and specially biotech stocks have respond accordingly.

    Innovative biotech business have adopted the change and are competing to make what could become a life-saving treatment for millions in the form of a vaccine.

    Some of the biggest winners of this transformative mega-trend are discussed below.

    Genocea Biosciences Inc. (NASDAQ:GNCA) shares were trading up 24.44% at $4.48 at the time of writing on Friday.

    Genocea Biosciences Inc. (NASDAQ:GNCA) share price went from a low point around $1.10 to briefly over $3.86 in past 52 weeks, though shares have since pulled back to $4.48. GNCA market cap has remained high, hitting $99.50M at the time of writing, giving it price-to-sales ratio of more than 110.

    If we look at the recent analyst rating GNCA, SVB Leerink initiated coverage on GNCA shares with an Outperform.

    Arbutus Biopharma Corporation (ABUS) last closed at $4.96, in a 52-week range of $0.82 to $6.48. Analysts have a consensus price target of $5.00.

    Ocugen Inc. (OCGN) stock soar by 32.85% to $0.38.

    Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Shares headed falling, lower as much as -3.97%. The most recent rating by ROTH Capital, on April 18, 2019, is at a Buy.

    Capricor Therapeutics Inc. (NASDAQ:CAPR) rose 29.31% after gaining more than $1.75 on Friday.

    Ampio Pharmaceuticals Inc. (AMPE) last closed at $0.96, in a 52-week range of $0.26 to $0.97.

    iBio Inc. (IBIO) last closed at $5.50, in a 52-week range of $0.05 to $7.45.

    Novan Inc. (NOVN) stock soar by 6.06% to $0.86. The most recent rating by Piper Jaffray, on January 06, 2020, is at a Neutral.

    Onconova Therapeutics Inc. (NASDAQ:ONTX) Shares headed falling, lower as much as -2.63%. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy.

    Actinium Pharmaceuticals Inc. (AMEX:ATNM) rose 7.45% after gaining more than $0.03 on Friday.

    Sesen Bio Inc. (SESN) last closed at $0.99, in a 52-week range of $0.37 to $1.54.

    VistaGen Therapeutics Inc. (VTGN) stock drop by -4.39% to $0.76. The most recent rating by Maxim Group, on June 27, 2018, is at a Buy.

    Qualigen Therapeutics Inc. (NASDAQ:QLGN) Shares headed rising, higher as much as 11.22%.

    PolarityTE Inc. (NASDAQ:PTE) rose 10.56% after gaining more than $0.17 on Friday.

    Matinas BioPharma Holdings Inc. (MTNB) last closed at $0.96, in a 52-week range of $0.49 to $2.49.